A Study to Learn About the Study Medicine Called PF-08653944 in Otherwise Healthy Chinese Adults With Overweight or Obesity

• Participants 18 years of age or older at screening who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and ECGs.
• BMI of 24-45 kg/m2; and a total body weight >50 kg (110 lb).
• Chinese participants are defined as individuals currently residing in mainland China who were born in China and have both parents of Chinese descent.

Exclusion Criteria:

• Pregnant or breastfeeding women, or those planning pregnancy during the study.
• Clinically significant medical conditions including hematologic, renal, endocrine, pulmonary, gastrointestinal (including pancreatitis, gallbladder disease, clinically relevant gastric emptying disorders), cardiovascular, hepatic, psychiatric, neurologic, or severe allergic diseases.
• Personal or first-degree family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2), or suspected MTC.
• Active or recent suicidal ideation in the past year, suicidal behavior within the past 5 years, or any psychiatric condition that increases risk in the investigator's judgment.
• Clinically significant gastric emptying abnormality or chronically taking drugs that directly affect GI motility.
• Acute gastrointestinal symptoms at screening or Day -1.
• Known hypersensitivity to PF-08653944, GLP-1 receptor agonists, or any excipients.
• Prior participation in any study involving PF-08653944 with at least one dose received.